We previously showed that broad inhibition of cyclophilins, through the use of multiple inhibitor compounds is beneficial in mouse models of NAFLD/NASH that feature prominent fibrosis [6, 7]. Here, PPIB is linked to metabolic dysfunction-associated steatotic liver disease.